Kadimastem Ltd (KDST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kadimastem Ltd (KDST) has a cash flow conversion efficiency ratio of -21.633x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-3.66 Million ≈ $-9.80K USD) by net assets (ILA169.00K ≈ $453.08 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KDST days of operational coverage to measure how many days the company can operate on defensive assets alone.
Kadimastem Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Kadimastem Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kadimastem Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kadimastem Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
-0.957x |
|
Fiplasto SA
BA:FIPL
|
-0.097x |
|
Xu Yuan Packaging Technology Co Ltd
TWO:8421
|
0.014x |
|
Lyka Labs Limited
NSE:LYKALABS
|
0.135x |
|
Eden Innovations Ltd
AU:EDE
|
0.987x |
|
Desert Mountain Energy Corp
V:DME
|
-0.007x |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
-0.364x |
|
NexgenRX Inc.
V:NXG
|
0.106x |
Annual Cash Flow Conversion Efficiency for Kadimastem Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Kadimastem Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Kadimastem Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA-29.15 Million ≈ $-78.14K |
ILA-2.75 Million ≈ $-7.39K |
0.095x | -96.28% |
| 2023-12-31 | ILA-4.36 Million ≈ $-11.69K |
ILA-11.09 Million ≈ $-29.72K |
2.543x | +104.15% |
| 2022-12-31 | ILA326.00K ≈ $873.99 |
ILA-20.00 Million ≈ $-53.61K |
-61.337x | -4278.97% |
| 2021-12-31 | ILA15.38 Million ≈ $41.24K |
ILA-21.55 Million ≈ $-57.76K |
-1.401x | -151.79% |
| 2020-12-31 | ILA-8.06 Million ≈ $-21.61K |
ILA-21.80 Million ≈ $-58.45K |
2.704x | +53.93% |
| 2019-12-31 | ILA-12.03 Million ≈ $-32.24K |
ILA-21.13 Million ≈ $-56.64K |
1.757x | +156.84% |
| 2018-12-31 | ILA6.74 Million ≈ $18.06K |
ILA-20.83 Million ≈ $-55.84K |
-3.091x | +33.28% |
| 2017-12-31 | ILA4.28 Million ≈ $11.47K |
ILA-19.83 Million ≈ $-53.16K |
-4.633x | -390.73% |
| 2016-12-31 | ILA-8.56 Million ≈ $-22.94K |
ILA-13.63 Million ≈ $-36.55K |
1.594x | -85.47% |
| 2015-12-31 | ILA-1.02 Million ≈ $-2.74K |
ILA-11.22 Million ≈ $-30.08K |
10.967x | +273.45% |
| 2014-12-31 | ILA1.55 Million ≈ $4.15K |
ILA-9.78 Million ≈ $-26.22K |
-6.323x | -241.15% |
| 2013-12-31 | ILA7.28 Million ≈ $19.50K |
ILA-13.48 Million ≈ $-36.15K |
-1.853x | -- |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more